De Cambra S, Corominas J, Prat T, Güell I, Ferrer L. 

PHH-1V (HIPRA), a recently granted EEA marketing authorisation vaccine, is based on the receptor binding domain of two SARS-CoV-2 variants, Beta and Alpha. PHH-1V has shown to be safe and well tolerated when used as third dose in previously vaccinated individuals with BNT162b2 (Comirnaty®, Pfizer/BioNTech), showing a more favourable reactogenicity profile compared to BNT162b21. Here, we present the reactogenicity of PHH-1V when used as fourth booster dose.